179262-62-5Relevant articles and documents
Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer
Rakitina, Tatiana V.,Zeifman, Alexey A.,Titov, Ilya Yu.,Svitanko, Igor V.,Lipkin, Aleksey V.,Stroylov, Viktor S.,Stroganov, Oleg V.,Novikov, Fedor N.,Chilov, Ghermes G.
, p. 287 - 289 (2012)
Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.